Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Treace Medical Concepts typically reports earnings before market open, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.

Historical price action around Treace earnings reveals significant volatility, with an average absolute Day 0 move of 5.27% and Day +1 move of 12.45%. The Day +1 reaction has proven particularly dramatic, more than doubling the initial Day 0 response and suggesting that investors often reassess their initial reactions as they digest management commentary and guidance.

The most extreme post-earnings moves occurred in November 2024 and November 2025, with Day +1 swings of 35.07% and -28.33% respectively, highlighting the stock's capacity for outsized reactions. More recently, the May 2026 report saw a 4.69% Day 0 gain followed by a -3.48% Day 1 reversal, while February 2026 produced an -11.43% Day 0 decline that extended to -10.75% on Day 1.

The average Day 0 trading range of 10.30% and Day +1 range of 16.84% underscore the heightened intraday volatility surrounding these events. Investors should prepare for potential double-digit percentage swings in either direction, with historical patterns suggesting the Day +1 session often determines the ultimate post-earnings trajectory.

Part 2.2: Options Market Expected Move

The options market is currently pricing in a 0.00% expected move for the upcoming earnings release, which stands in stark contrast to the stock's historical average absolute move of 5.27% on Day 0 and 12.45% on Day +1. This absence of implied volatility pricing suggests either extremely thin options liquidity or data unavailability, leaving investors without a clear market-derived expectation for post-earnings movement.

Part 3: What Analysts Are Saying

Analyst sentiment on Treace Medical Concepts reflects mixed conviction, with a consensus rating of 3.00 (Hold) and an average price target of $4.67. The current analyst breakdown shows 1 Strong Buy, 4 Hold, and 1 Strong Sell rating among the 6 analysts covering the stock, indicating a lack of strong directional conviction in either direction.

The average price target of $4.67 implies approximately 6.6% upside from the current price of $4.38, suggesting modest appreciation potential if the company meets expectations. However, the wide range of price targets—from a low of $3.00 to a high of $7.00—reveals significant disagreement among analysts about the company's valuation, with the high estimate implying 59.8% upside while the low estimate suggests 31.5% downside risk.

Analyst sentiment has remained unchanged over the past month, with the 3.00 consensus rating holding steady and no meaningful shift in the distribution of buy, hold, and sell recommendations. The stability in ratings suggests analysts are waiting for clearer evidence of either accelerating growth or meaningful progress toward profitability before adjusting their stances. One analyst moved from Hold to Strong Buy in the past month, but this was offset by another downgrade, leaving the overall sentiment balanced at neutral.

Part 4: Technical Picture

Treace Medical Concepts enters earnings with strong technical momentum, as reflected in the Barchart Technical Opinion showing an 88% Buy signal, up from 80% just one week ago and matching the month-ago reading. This improvement in the near-term signal suggests building positive momentum heading into the release.

Timeframe Analysis:

• Short-term (100% Buy): Strong buy signal indicates robust near-term momentum with all short-term indicators aligned positively
• Medium-term (100% Buy): Unanimous buy reading confirms the intermediate-term trend remains firmly supportive
• Long-term (50% Buy): Moderate buy signal reflects a more balanced longer-term outlook, suggesting some caution about sustainability

Trend Characteristics: The combination of Average strength and Average direction indicates a steady, moderate uptrend without extreme momentum characteristics—a relatively stable technical environment heading into the volatility of an earnings release.

The stock is trading at $4.38, positioned above its 10-day ($4.34), 20-day ($4.32), 50-day ($4.11), 100-day ($2.99), and 200-day ($3.01) moving averages, though it sits below the 5-day moving average ($4.58). This broad-based support across longer-term moving averages confirms the uptrend, while the slight pullback from the 5-day average suggests recent consolidation.

The stock has demonstrated impressive longer-term momentum, trading 45.8% above its 200-day moving average and 46.5% above its 100-day average, reflecting a sustained recovery from earlier lows. The 50-day moving average at $4.11 provides nearby support, while the recent high near $4.58 (the 5-day moving average) represents immediate resistance. The overall technical setup is supportive heading into earnings, with multiple layers of moving average support below current levels providing a cushion against potential disappointment, though the strong recent run-up also means the stock has less room for error if results or guidance disappoint.